Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 64.48 Million USD | 245.17% |
| 2022 | 18.68 Million USD | -56.63% |
| 2021 | 43.08 Million USD | 0.37% |
| 2020 | 42.92 Million USD | 10.76% |
| 2019 | 38.75 Million USD | 1.5% |
| 2018 | 38.17 Million USD | 9.59% |
| 2017 | 34.83 Million USD | 4.44% |
| 2016 | 33.35 Million USD | 5631.62% |
| 2015 | 582 Thousand USD | -98.24% |
| 2014 | 33.06 Million USD | 935.22% |
| 2013 | 3.19 Million USD | 354.34% |
| 2012 | 703 Thousand USD | -76.54% |
| 2011 | 2.99 Million USD | -37.15% |
| 2010 | 4.76 Million USD | -54.6% |
| 2009 | 10.5 Million USD | -30.03% |
| 2008 | 15 Million USD | 48306.45% |
| 2007 | 31 Thousand USD | -27.91% |
| 2006 | 43 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 69.73 Million USD | 0.42% |
| 2024 Q1 | 69.43 Million USD | 7.67% |
| 2023 FY | 64.48 Million USD | 245.17% |
| 2023 Q3 | 64.22 Million USD | 0.42% |
| 2023 Q2 | 63.95 Million USD | 44.85% |
| 2023 Q4 | 64.48 Million USD | 0.42% |
| 2023 Q1 | 44.15 Million USD | 136.32% |
| 2022 Q2 | 29.29 Million USD | -19.17% |
| 2022 Q4 | 18.68 Million USD | -16.93% |
| 2022 Q1 | 36.24 Million USD | -15.87% |
| 2022 FY | 18.68 Million USD | -56.63% |
| 2022 Q3 | 22.49 Million USD | -23.23% |
| 2021 Q4 | 43.08 Million USD | 0.56% |
| 2021 FY | 43.08 Million USD | 0.37% |
| 2021 Q1 | 42.8 Million USD | -0.28% |
| 2021 Q2 | 42.59 Million USD | -0.49% |
| 2021 Q3 | 42.83 Million USD | 0.57% |
| 2020 Q3 | 42.91 Million USD | 0.21% |
| 2020 Q2 | 42.82 Million USD | 3.2% |
| 2020 Q1 | 41.49 Million USD | 7.07% |
| 2020 Q4 | 42.92 Million USD | 0.03% |
| 2020 FY | 42.92 Million USD | 10.76% |
| 2019 Q4 | 38.75 Million USD | 9.79% |
| 2019 Q2 | 38.46 Million USD | 0.36% |
| 2019 Q3 | 35.29 Million USD | -8.22% |
| 2019 FY | 38.75 Million USD | 1.5% |
| 2019 Q1 | 38.32 Million USD | 0.37% |
| 2018 Q3 | 38.02 Million USD | 0.6% |
| 2018 Q1 | 37.53 Million USD | 7.75% |
| 2018 FY | 38.17 Million USD | 9.59% |
| 2018 Q4 | 38.17 Million USD | 0.4% |
| 2018 Q2 | 37.79 Million USD | 0.7% |
| 2017 Q3 | 34.21 Million USD | 1.16% |
| 2017 Q2 | 33.82 Million USD | 0.68% |
| 2017 Q1 | 33.59 Million USD | 0.7% |
| 2017 FY | 34.83 Million USD | 4.44% |
| 2017 Q4 | 34.83 Million USD | 1.82% |
| 2016 Q2 | 486 Thousand USD | -13.37% |
| 2016 FY | 33.35 Million USD | 5631.62% |
| 2016 Q3 | 33.82 Million USD | 6860.08% |
| 2016 Q4 | 33.35 Million USD | -1.38% |
| 2016 Q1 | 561 Thousand USD | -3.61% |
| 2015 Q2 | 26.68 Million USD | -10.47% |
| 2015 FY | 582 Thousand USD | -98.24% |
| 2015 Q4 | 582 Thousand USD | -98.31% |
| 2015 Q3 | 34.44 Million USD | 29.08% |
| 2015 Q1 | 29.8 Million USD | -9.85% |
| 2014 Q2 | 9.31 Million USD | 235.24% |
| 2014 Q1 | 2.77 Million USD | -13.02% |
| 2014 FY | 33.06 Million USD | 935.22% |
| 2014 Q4 | 33.06 Million USD | -2.57% |
| 2014 Q3 | 33.93 Million USD | 264.42% |
| 2013 Q1 | 153 Thousand USD | -78.24% |
| 2013 Q4 | 3.19 Million USD | -8.01% |
| 2013 Q2 | 3.88 Million USD | 2441.83% |
| 2013 FY | 3.19 Million USD | 354.34% |
| 2013 Q3 | 3.47 Million USD | -10.72% |
| 2012 Q2 | 1.79 Million USD | -23.11% |
| 2012 Q4 | 703 Thousand USD | -43.76% |
| 2012 Q1 | 2.33 Million USD | -18.69% |
| 2012 Q3 | 1.25 Million USD | -30.28% |
| 2012 FY | 703 Thousand USD | -76.54% |
| 2011 Q3 | 3.5 Million USD | -12.48% |
| 2011 FY | 2.99 Million USD | -37.15% |
| 2011 Q1 | 4.16 Million USD | -12.69% |
| 2011 Q4 | 2.86 Million USD | -18.08% |
| 2011 Q2 | 4 Million USD | -3.89% |
| 2010 Q4 | 4.76 Million USD | 0.0% |
| 2010 Q2 | - USD | -100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | 9 Million USD | -14.29% |
| 2010 FY | 4.76 Million USD | -54.6% |
| 2009 Q3 | 12 Million USD | 0.0% |
| 2009 FY | 10.5 Million USD | -30.03% |
| 2009 Q4 | 10.5 Million USD | -12.51% |
| 2008 Q4 | 15 Million USD | 0.0% |
| 2008 FY | 15 Million USD | 48306.45% |
| 2008 Q2 | 14 Thousand USD | -99.91% |
| 2008 Q1 | 15.02 Million USD | 0.0% |
| 2007 FY | 31 Thousand USD | -27.91% |
| 2006 FY | 43 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -2024.605% |
| Safety Shot Inc | 304.9 Thousand USD | -21050.384% |
| Bright Green Corporation | 201.78 Thousand USD | -31859.58% |
| Embecta Corp. | 1.62 Billion USD | 96.032% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 79.175% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 29.192% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 86.838% |
| Dynavax Technologies Corporation | 252.41 Million USD | 74.452% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 87.142% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -383.934% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 87.449% |
| PainReform Ltd. | 30 Thousand USD | -214863.333% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -11863.787% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -11863.787% |
| SCYNEXIS, Inc. | 12.15 Million USD | -430.381% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -54958.098% |
| Journey Medical Corporation | 14.62 Million USD | -341.041% |
| Alpha Teknova, Inc. | 13.25 Million USD | -386.673% |
| Procaps Group, S.A. | 28.41 Million USD | -126.994% |
| Theratechnologies Inc. | 51.26 Million USD | -25.805% |
| Harrow Health, Inc. | 183.17 Million USD | 64.793% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -74025.287% |
| Biofrontera Inc. | 804 Thousand USD | -7921.02% |
| DURECT Corporation | 2.7 Million USD | -2286.714% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -94.267% |
| Cronos Group Inc. | 1.55 Million USD | -4036.562% |
| OptiNose, Inc. | 611 Thousand USD | -10454.664% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 87.058% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -88.619% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -14073.407% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -6.163% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -404.445% |
| Radius Health, Inc. | 339.66 Million USD | 81.014% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -528.67% |
| Phibro Animal Health Corporation | 458.28 Million USD | 85.928% |
| Procaps Group S.A. | 28.41 Million USD | -126.994% |
| Alvotech | 1.02 Billion USD | 93.725% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -887.278% |
| Viatris Inc. | 16.18 Billion USD | 99.602% |
| Rockwell Medical, Inc. | 8.29 Million USD | -677.632% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -492.893% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -19093.669% |
| Tilray Brands, Inc. | 287.93 Million USD | 77.603% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 46.487% |
| Shineco, Inc. | 10.01 Million USD | -543.774% |
| PetIQ, Inc. | 437.82 Million USD | 85.27% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -30609.048% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 75.033% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -67.443% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -47638.158% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -840.434% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -8856.806% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -286721.74% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -96.853% |
| Hempacco Co., Inc. | 5.93 Million USD | -987.321% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 93.725% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -14.716% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 89.533% |
| Currenc Group, Inc. | 2.5 Million USD | -2472.384% |
| Kamada Ltd. | 7.43 Million USD | -767.021% |
| Indivior PLC | 235.66 Million USD | 72.636% |
| Evoke Pharma, Inc. | 5 Million USD | -1189.78% |
| Flora Growth Corp. | 942 Thousand USD | -6745.966% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -286721.74% |
| Evolus, Inc. | 120.35 Million USD | 46.419% |
| HUTCHMED (China) Limited | 48.18 Million USD | -33.825% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 89.055% |
| Akanda Corp. | 2.49 Million USD | -2482.499% |